ClinPGx Blog (Page 38)

Sign in Subscribe

More issues

FDA-Approved Drug Labels, Pharmacogenomics and PharmGKB Evaluation

FDA-approved drug label standardization and pharmacogenomics People often use the wording "FDA drug labels" instead of "FDA-approved drug labels." To be clear, the FDA does not write drug labels; it is the responsibility of the drug company to provide them. The FDA reviews and approves labels,

Viva La Evidence

We came across this brilliant music video “Viva La Evidence” by Dr. James McCormack. It’s a parody of Coldplay's Viva La Vida and the lyrics cover many important topics of evidence based medicine, its history, principles and aims. What a fun way to explain the hierarchy of

Venlafaxine Pathway published in PG&G

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) marketed for the treatment of depression disorders. We recently have published the Venlafaxine Pathway summary in the Pharmacogenetics and Genomics Journal.The article describes the metabolism of venlafaxine, with cytochrome P450 2D6 (CYP2D6) being the major enzyme involved in the formation of its

NIH funds ClinGen: a resource to establish which genetic variants are clinically relevant

The NIH (NHGRI and NICHD) has awarded more than $25 million over the course of 4 years for the development of the Clinical Genome Resource (ClinGen). The aim of ClinGen is to provide a framework for the evaluation of genetic variants that are clinically relevant, working with the NCBI which

The Curation Economy

In an October 7th article in The Huffington Post blog section, Steve Rosenbaum discusses the development of a so-called "Curation Economy". Rosenbaum writes that the creation of content on the web is increasing at an exponential rate, leading to a massive amount of raw and unfiltered data. This

CPIC publishes guidelines for IFNL3 (IL28B) and peginterferon alpha based regimens

Guidelines regarding the use of IFNL3 (formerly known as IL28B) genotypes in peginterferon alpha based therapies have been accepted for publication in the Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC). Hepatitis C virus (HCV) infection affects more than 150 million people worldwide and is one of

CYP2D6 genotype and tamoxifen response: meta-analysis of heterogeneous population

Tamoxifen treatment results in substantial inter-individual variability of outcome, possibly due to genetic variability in CYP2D6. The clinical usefulness of CYP2D6 genotyping for prediction of tamoxifen outcome has not been established because of conflicting reports. This controversy is well illustrated by secondary analyses from 3 large adjuvant tamoxifen trials (ATAC,

New EGFR VIP Summary Published in PG&G

The epidermal growth factor receptor (EGFR) is involved in the growth of many epithelial malignancies, such as non-small-cell lung cancer (NSCLC), pancreatic and colorectal cancer. It has therefore been a key target for the development of cancer therapeutics. These include tyrosine kinase inhibitors (gefinitib and erolinitib) and monoclonal antibodies (cetuximab

CPIC publishes guidelines for DPYD and fluoropyrimidines

The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published guidelines for the use of genetic test results for DPYD in fluoropyrimidine dosing. The guideline in Clinical Pharmacology and Therapeutics recommends strategies for drug dosing or alternative drug choice in cancer patients who have known variants in the dihydropyrimidine dehydrogenase (DPYD) gene

Tamoxifen Pharmacokinetic Pathway Published

Tamoxifen, a selective estrogen receptor modulator, is used in the treatment and prevention of estrogen receptor positive breast cancer. The paper detailing the pharmacokinetic pathway of tamoxifen has been published by PG&G and can be found online. The pathway can also be found on our website. View all